Advanced

SLUG transcription factor : A pro-survival and prognostic factor in gastrointestinal stromal tumour

Pulkka, Olli Pekka ; Nilsson, Bengt ; Sarlomo-Rikala, Maarit ; Reichardt, Peter ; Eriksson, Mikael LU ; Hall, Kirsten Sundby ; Wardelmann, Eva ; Vehtari, Aki ; Joensuu, Heikki and Sihto, Harri (2017) In British Journal of Cancer 116(9). p.1195-1202
Abstract

Background:The SLUG transcription factor has been linked with the KIT signalling pathway that is important for gastrointestinal stromal tumour (GIST) tumourigenesis. Its clinical significance in GIST is unknown.Methods:Influence of SLUG expression on cell proliferation and viability were investigated in GIST48 and GIST882 cell lines. The association between tumour SLUG expression in immunohistochemistry and recurrence-free survival (RFS) was studied in two clinical GIST series, one with 187 patients treated with surgery alone, and another one with 313 patients treated with surgery and adjuvant imatinib.Results:SLUG downregulation inhibited cell proliferation, induced cell death in both cell lines, and sensitised GIST882 cells to lower... (More)

Background:The SLUG transcription factor has been linked with the KIT signalling pathway that is important for gastrointestinal stromal tumour (GIST) tumourigenesis. Its clinical significance in GIST is unknown.Methods:Influence of SLUG expression on cell proliferation and viability were investigated in GIST48 and GIST882 cell lines. The association between tumour SLUG expression in immunohistochemistry and recurrence-free survival (RFS) was studied in two clinical GIST series, one with 187 patients treated with surgery alone, and another one with 313 patients treated with surgery and adjuvant imatinib.Results:SLUG downregulation inhibited cell proliferation, induced cell death in both cell lines, and sensitised GIST882 cells to lower imatinib concentrations. SLUG was expressed in 125 (25.0%) of the 500 clinical GISTs evaluated, and expression was associated with several factors linked with unfavourable prognosis. SLUG expression was associated with unfavourable RFS both when patients were treated with surgery alone (HR=3.40, 95% CI=1.67-6.89, P=0.001) and when treated with surgery plus adjuvant imatinib (HR=1.83, 95% CI=1.29-2.60, P=0.001).Conclusions:GIST patients with high tumour SLUG expression have unfavourable RFS. SLUG may mediate pro-survival signalling in GISTs.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Cancer
volume
116
issue
9
pages
1195 - 1202
publisher
Nature Publishing Group
external identifiers
  • pmid:28334729
  • scopus:85015944801
ISSN
0007-0920
DOI
10.1038/bjc.2017.82
language
English
LU publication?
yes
id
4f5af473-5b3c-4f3e-8dae-fe8ae5fe6100
date added to LUP
2020-02-24 15:18:08
date last changed
2020-11-10 05:38:21
@article{4f5af473-5b3c-4f3e-8dae-fe8ae5fe6100,
  abstract     = {<p>Background:The SLUG transcription factor has been linked with the KIT signalling pathway that is important for gastrointestinal stromal tumour (GIST) tumourigenesis. Its clinical significance in GIST is unknown.Methods:Influence of SLUG expression on cell proliferation and viability were investigated in GIST48 and GIST882 cell lines. The association between tumour SLUG expression in immunohistochemistry and recurrence-free survival (RFS) was studied in two clinical GIST series, one with 187 patients treated with surgery alone, and another one with 313 patients treated with surgery and adjuvant imatinib.Results:SLUG downregulation inhibited cell proliferation, induced cell death in both cell lines, and sensitised GIST882 cells to lower imatinib concentrations. SLUG was expressed in 125 (25.0%) of the 500 clinical GISTs evaluated, and expression was associated with several factors linked with unfavourable prognosis. SLUG expression was associated with unfavourable RFS both when patients were treated with surgery alone (HR=3.40, 95% CI=1.67-6.89, P=0.001) and when treated with surgery plus adjuvant imatinib (HR=1.83, 95% CI=1.29-2.60, P=0.001).Conclusions:GIST patients with high tumour SLUG expression have unfavourable RFS. SLUG may mediate pro-survival signalling in GISTs.</p>},
  author       = {Pulkka, Olli Pekka and Nilsson, Bengt and Sarlomo-Rikala, Maarit and Reichardt, Peter and Eriksson, Mikael and Hall, Kirsten Sundby and Wardelmann, Eva and Vehtari, Aki and Joensuu, Heikki and Sihto, Harri},
  issn         = {0007-0920},
  language     = {eng},
  month        = {04},
  number       = {9},
  pages        = {1195--1202},
  publisher    = {Nature Publishing Group},
  series       = {British Journal of Cancer},
  title        = {SLUG transcription factor : A pro-survival and prognostic factor in gastrointestinal stromal tumour},
  url          = {http://dx.doi.org/10.1038/bjc.2017.82},
  doi          = {10.1038/bjc.2017.82},
  volume       = {116},
  year         = {2017},
}